[PDF] Top 20 Identificación de las especies del género Mycobacterium mediante proteómica

... Figure 1 Structures of native GLP-1, exenatide, and liraglutide. The N-terminal dipeptide “HA” (in green letters) of GLP-1 and liraglutide is the proteolytic cleavage site for DPP 4. ... See full document

... gain. GLP-1 receptor agonists have rapidly established a place as add-on therapy to other oral agents, in preference to a direct move onto insulin ...strategies. GLP-1 ... See full document

... 2 diabetes mellitus (T2DM), and yet, challenges in the management of the disease ...(dopamine-2 agonists), and (6) an unknown primary physiological action (bile acid ...(GLP-1) ... See full document

... (GLP-1) receptor agonists are a class of drugs that are licensed for the treatment of Type 2 diabetes (Baggio 2007; Campbell 2013; Doyle 2003; Holst ...a receptor (a protein ... See full document

... 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, and some types of ...the development of new ... See full document

... 2 diabetes mellitus) ...The development of effective pharmacological treatments for obesity has thus far proven unsuccessful ...peptide 1 (GLP-1), may have potential as an antiobesity ... See full document

... (short-acting) GLP-1 receptor agonist that is currently in development for the treatment of type 2 diabetes, and was recently (February 2013) granted marketing authorization by the ... See full document

... or 1 g/kg per day to Wistar rats for 13 weeks, the results indicated that the maximum dose at which no toxic or adverse event was recorded (no-observed-adverse-effect level, NOAEL) was that of 1 g/kg ...at ... See full document

... the management of type 2 diabetes, GLP-1 receptor agonists can be introduced at multiple stages throughout type 2 diabetes treatment ...(1). GLP-1 ... See full document

... he management of patients with type 2 diabetes has become more complex in recent ...2 diabetes means that, eventually, pharmacological agents in addition to metformin will be required for successful ... See full document

... carefully monitor glucose levels (including PPG), weight, renal function, and blood pressure. Elderly persons are more likely to have renal dysfunction than other adults. Therefore, medications such as metformin should ... See full document

... Exenatide extended release (ER) contains the exendin- 4 molecule interlinked with microspheres of poly-(D, L-lactide-co-glycolide) polymers, degradable material that had previously been used in absorbable sutures. The ... See full document

... the GLP-1RA class, summarizing currently available long-term efficacy and safety data from prospective phase 3 clinical studies of at least 76 weeks’ ...six GLP-1RAs currently approved for use in the United ... See full document

... the role played by each component varies widely between patients and even within the same patient at different stages of the ...2 diabetes treated with insulin after acute myocardial infarction showed that ... See full document

... crucial role in the induction and progression of diabetic nephropathy ...of development of oxidative ...major role in the progression of VED and nephropathy ...that diabetes increases the ... See full document

... the GLP-1 receptor agonists outlined in Table 2, therapy may individual- ized to provide each patient with the best opportunity for successful ... See full document

... 2 diabetes that is dosed one time per week, contains exenatide encapsulated in microspheres of a dissolv- able matrix, which release active agent slowly and continuously into the circulation follow- ing ... See full document

... DCE studies. This finding is an area for future research, and should be replicated with other medication comparisons and in other disease areas. For now, the results suggest that we should be cautious about taking the ... See full document

... and GLP-1RA for the treatment of ...proteins, GLP-1 or glucagon- like peptides, and ...of GLP-1RA or SGLT2-I versus placebo, with or without background MET ...on GLP-1RA or SGLT2-I used ... See full document

... Insulin not only controls glucose utilization in the periphery (Hallschmid et al., 2004; Benedict et al., 2011; Hallschmid et al., 2012; Ott et al., 2012), but has additional roles in the brain. Insulin receptors have ... See full document